356 related articles for article (PubMed ID: 32517874)
1. Just eat it: A review of CD47 and SIRP-α antagonism.
Oronsky B; Carter C; Reid T; Brinkhaus F; Knox SJ
Semin Oncol; 2020; 47(2-3):117-124. PubMed ID: 32517874
[TBL] [Abstract][Full Text] [Related]
2. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
3. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
5. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
6. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
8. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
9. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
10. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
11. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
12. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
13. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
14. Is CD47 an innate immune checkpoint for tumor evasion?
Liu X; Kwon H; Li Z; Fu YX
J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
[TBL] [Abstract][Full Text] [Related]
15. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
16. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC; Shi W; Shi JJ; Lu JJ
J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
[TBL] [Abstract][Full Text] [Related]
17. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.
Zhou X; Jiao L; Qian Y; Dong Q; Sun Y; Zheng WV; Zhao W; Zhai W; Qiu L; Wu Y; Wang H; Gao Y; Chen J
Biomolecules; 2021 May; 11(5):. PubMed ID: 34068552
[TBL] [Abstract][Full Text] [Related]
18. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
19. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience.
Folkes AS; Feng M; Zain JM; Abdulla F; Rosen ST; Querfeld C
Curr Opin Oncol; 2018 Sep; 30(5):332-337. PubMed ID: 29994903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
